Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

NewAmsterdam Pharma (NAMS) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$0.61.

  • NewAmsterdam Pharma's EPS (Basic) fell 23888.89% to -$0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.05, marking a year-over-year increase of 888.89%. This contributed to the annual value of -$2.56 for FY2024, which is 1906.98% down from last year.
  • Per NewAmsterdam Pharma's latest filing, its EPS (Basic) stood at -$0.61 for Q3 2025, which was down 23888.89% from -$0.15 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's EPS (Basic) ranged from a high of -$0.15 in Q2 2025 and a low of -$1.06 during Q1 2024
  • Moreover, its 3-year median value for EPS (Basic) was -$0.51 (2023), whereas its average is -$0.53.
  • In the last 5 years, NewAmsterdam Pharma's EPS (Basic) skyrocketed by 6842.11% in 2024 and then plummeted by 23888.89% in 2025.
  • NewAmsterdam Pharma's EPS (Basic) (Quarter) stood at -$0.6 in 2023, then plummeted by 58.33% to -$0.95 in 2024, then surged by 35.79% to -$0.61 in 2025.
  • Its last three reported values are -$0.61 in Q3 2025, -$0.15 for Q2 2025, and -$0.34 during Q1 2025.